New ideas about the pathogenesis of osteoarthritis, the role of metabolic disorders

The article highlights the current data on the prevalence and pathogenesis of osteoarthritis (OA), presents a new definition of the disease, research results on the heterogeneity of OA, its relationship with obesity and metabolic syndrome. Obesity is one of the main factors in the development and more rapid progression of OA, and the presence of metabolic syndrome not only increases the risk of developing the disease, but also determines its severity. It is noted that with an increase of the components of the metabolic syndrome, the severity of OA increases. Therefore, hyperuricemia is associated with the presence of osteophytes and the progression of osteoarthritis, hyperglycemia - with the severity of the clinical manifestations and radiological progression. Much attention is given to the treatment of patients with OA and The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) recommendations for the treatment of knee joints OA updated in 2019. In which for the first time a symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) are assigned as the basis in the treatment of OA. The data on the effectiveness of some drugs from this group are presented. The glycosaminoglycan-peptide complex, which contains pharmacologically high-quality chondroitin sulfate when administered intramuscularly, has a significant effect on the symptoms, and in case of continued use, slows the progression of OA. The multicenter open-label prospective study of diacerein in patients with knee-joint OA combined with metabolic syndrome showed that during therapy pain syndrome and stiffness are reduced, and functional condition of the joints and quality of life of patients improves quickly and significantly. In addition, the positive effect of the drug on some components of the metabolic syndrome was demonstrated: a significant decrease in body mass index, low density lipoproteins, triglycerides, glucose and uric acid.

1. Балабанова Р.М., Дубинина Т.В., Эрдес Ш.Ф. Динамика заболеваемости ревматическими заболеваниями взрослого населения России за 2010–2014 гг. Научно-практическая ревматология. — 2016. — Т.54. — №3. — С.266–270. [Balabanova R.M., Dubinina T.V., Erdes S.F. Trends in the incidence of rheumatic diseases in the adult population of Russia over 2010–2014 Rheumatology Science and Practice. 2016;54(3):266-270. (In Russ.)].

2. Fernandes JC, Martel-Pelletier J, Pelletier J-P. The role of cytokines in osteoarthritis pathophysiology. Biorheology. 2002;39(1-2):237-246. PMID: 12082286

3. Malemud CJ. Cytokines as Therapeutic Targets for Osteoarthritis. BioDrugs. 2004;18(1):23-35. doi: 10.2165/00063030-200418010-00003

4. Blom A, van der Kraan P, van den Berg W. Cytokine Targeting in Osteoarthritis. Curr Drug Targets. 2007;8(2):283-292. doi: 10.2174/138945007779940179

5. Fan Z, Soder S, Oehler S, et al. Activation of Interleukin-1 Signaling Cascades in Normal and Osteoarthritic Articular Cartilage. Am J Pathol. 2007;171(3):938-946. doi: 10.2353/ajpath.2007.061083

6. Nathan C, Xie Q. Nitric oxide synthases: Roles, tolls, and controls. Cell. 1994;78(6):915-918. doi: 10.1016/0092-8674(94)90266-6

7. Daheshia M, Yao JQ. The Interleukin 1β Pathway in the Pathogenesis of Osteoarthritis. J Rheumatol. 2008;35(12):2306-2312. doi: 10.3899/jrheum.080346

8. Mobasheri A, Bay-Jensen A-C, van Spil WE, Larkin J, Levesque MC. Osteoarthritis Year in Review 2016: biomarkers (biochemical markers). Osteoarthr Cartil. 2017;25(2):199-208. doi: 10.1016/j.joca.2016.12.016

9. Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthr Cartil. 2015;23(8):1233-1241. doi: 10.1016/j.joca.2015.03.036

10. Zheng H, Chen C. Body mass index and risk of knee osteoarthritis: systematic review and meta-analysis of prospective studies. BMJ Open. 2015;5(12):e007568. doi: 10.1136/bmjopen-2014-007568

11. Fu Y., Griffin T.M. Obesity, Osteoarthritis and Aging: The Biomechanical Links. In: Gefen A., Benayahu D., editors. The Mechanobiology of Obesity and Related Diseases. Studies in Mechanobiology, Tissue Engineering and Biomaterials, vol 16. Springer, Cham; 2014. p.181-201. doi: 10.1007/8415_2014_178

12. Wang H, Cheng Y, Shao D, et al. Metabolic Syndrome Increases the Risk for Knee Osteoarthritis: A Meta-Analysis. Evidence-Based Complement Altern Med. 2016;2016:1-7. doi: 10.1155/2016/7242478

13. Мычка В.Б., Жернакова Ю.В., Чазова И.Е. Рекомендации экспертов всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома (второй пересмотр) // Dоктор.Ру. – 2010. – №3. – С.15-18. [Mychka VB, Zhernakova YuV, Chazova IYe. Society of Cardiology of the Russian Federation: Guidelines on diagnosis and treatment of the metabolic syndrome (2nd revision). Doktor.ru. 2010;(3):15-18. (In Russ.)].

14. Yoshimura N, Muraki S, Oka H, et al. Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. Osteoarthr Cartil. 2012;20(11):1217-1226. doi: 10.1016/j.joca.2012.06.006

15. Chadha R. Revealed aspect of metabolic osteoarthritis. J Orthop. 2016;13(4):347-351. doi: 10.1016/j.jor.2016.06.029

16. Farnaghi S, Crawford R, Xiao Y, Prasadam I. Cholesterol metabolism in pathogenesis of osteoarthritis disease. Int J Rheum Dis. 2017;20(2):131-140. doi: 10.1111/1756-185X.13061

17. Dell’Isola A, Allan R, Smith SL, Marreiros SSP, Steultjens M. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet Disord. 2016;17(1):425. doi: 10.1186/s12891-016-1286-2

18. Ding X, Zeng C, Wei J, et al. The associations of serum uric acid level and hyperuricemia with knee osteoarthritis. Rheumatol Int. 2016;36(4):567-573. doi: 10.1007/s00296-015-3418-7

19. Krasnokutsky S, Oshinsky C, Attur M, et al. Serum Urate Levels Predict Joint Space Narrowing in Non‐Gout Patients With Medial Knee Osteoarthritis. Gefen A, Benayahu D, eds. Arthritis Rheumatol. 2017;69(6):1213-1220. doi: 10.1002/art.40069

20. Hart DJ, Doyle D V, Spector TD. Association between metabolic factors and knee osteoarthritis in women: the Chingford Study. Gefen A, Benayahu D, eds. J Rheumatol. 1995;22(6):1118-1123. PMID: 7674240

21. Стребкова Е.А., Алексеева Л.И. Остеоартроз и метаболический синдром // Фарматека. — 2015. — №17. — С.15–19. [Strebkova EA, Alekseeva LI. Osteoartroz i metabolicheskii sindrom. Farmateka. 2015;(17):15-19. (In Russ.)]

22. Lee KM, Chung CY, Sung KH, et al. Risk Factors for Osteoarthritis and Contributing Factors to Current Arthritic Pain in South Korean Older Adults. Gefen A, Benayahu D, eds. Yonsei Med J. 2015;56(1):124. doi: 10.3349/ymj.2015.56.1.124

23. Bruyère O, Cooper C, Pelletier J-P, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44(3):253-263. doi: 10.1016/j.semarthrit.2014.05.014

24. Bruyère O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;35(12):2306-2312. doi: 10.1016/j.semarthrit.2019.04.008

25. Singh JA, Wilt T, MacDonald R. Chondroitin for osteoarthritis. In: Singh JA, editor. Studies in Mechanobiology, Tissue Engineering and Biomaterials. Cochrane Database of Systematic Reviews. Vol 56. Chichester, UK: John Wiley & Sons, Ltd; 2006:124. doi: 10.1002/14651858.CD005614

26. Zegels B, Crozes P, Uebelhart D, et al. Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthr Cartil. 2013;21(1):22-27. doi: 10.1016/j.joca.2012.09.017

27. Pavelká K, Gatterová J, Gollerova V, Urbanová Z, Sedlácková M, Altman R. A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon®) as a structure modifying therapy in osteoarthritis of the hip and knee. Osteoarthr Cartil. 2000;8(5):335-342. doi: 10.1053/joca.1999.0307

28. Jay Bollet A. Stimulation of Protein–Chondroitin Sulfate Synthesis by Normal and Osteoarthritic Articular Cartilage. Arthritis Rheum. 1968;11(5):663-673. doi: 10.1002/art.1780110509

29. Burkhardt D, Ghosh P. Laboratory evaluation of antiarthritic drugs as potential chondroprotective agents. Semin Arthritis Rheum. 1987;17(2 Suppl 1):3-34. PMID: 3333893

30. Howell DS, Altman RD. Cartilage repair and conservation in osteoarthritis. A brief review of some experimental approaches to chondroprotection. Rheum Dis Clin North Am. 1993;19(3):713-724. PMID: 8210583

31. Annefeld M, Erne B. The mode of action of a glycosaminoglycan-peptide-complex (Rumalon®) on articular cartilage of the rat in vivo. Clin Rheumatol. 1987;6(3):340-349. doi: 10.1007/BF02206832

32. Алексеева Л.И., Карякин А.Н., Смирнов А.В., Беневоленская Л.И. Применение Румалона при гонартрозе // Терапевтический архив. — 1997. — №5. — С.64-66. [Alekseeva LI, Karyakin AN, Smirnov AV, Benevolenskaya LI. Primenenie Rumalona pri gonartroze. Therapeutic archive. 1997;(5):64-66. (In Russ.)].

33. Rejholec V. Long-term studies of antiosteoarthritic drugs: an assessment. Semin Arthritis Rheum. 1987;17(2 Suppl 1):35-53. PMID: 3333894

34. Rejholec V, Králová M. Langzeitbehandlung der Coxarthrose mit Rumalon®. Aktuelle Rheumatol. 1984;9(S 2):139-148. doi: 10.1055/s-2008-1048133

35. Martel-Pelletier J, Pelletier J-P. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis. 2010;2(2):95-104. doi: 10.1177/1759720X09359104

36. Алексеева Л.И., Таскина Е.А., Кашеварова Н.Г., и др. Остеоартрит коленных суставов и метаболический синдром: новые подходы к терапии // Научно-практическая ревматология. — 2018. — Т.56. — №2. — С.157-163. [Alekseeva LI, Taskina EA, Kashevarova NG, et al. Knee osteoarthritis and metabolic syndrome: new approaches to therapy. Rheumatology Science and Practice. 2018;56(2):157-163. (In Russ.)].

37. Honvo G, Reginster J-Y, Rannou F, et al. Safety of Intra-articular Hyaluronic Acid Injections in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Singh JA, ed. Drugs Aging. 2019;36(S1):101-127. doi: 10.1007/s40266-019-00657-w